{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:24:37Z","timestamp":1790364277664,"version":"4.1.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,16]]},"abstract":"<jats:p>Most hepatocellular carcinomas (HCC) treated by transcatheter arterial chemoembolization with drug-eluting beads (DEB-TACE) are characterized by coagulation necrosis; therefore, it is often difficult to distinguish enhancement in the arterial phase that would lead to false negative evaluation. This study aimed to evaluate the specificity and sensitivity of the difference value of multiphase contrast-enhanced computed tomography (CECT) in predicting residual tumor activity in HCC lesions after DEB-TACE. This retrospective diagnostic study analyzed CECT images of 73 HCC lesions in 57 patients 20 to 40 days (average 28 days) after DEB-TACE treatment at our Hospital from January to December 2019. Postoperative pathology or digital subtraction angiography images were used as references. Residual tumor activity after the first intervention was determined based on the presence of tumor staining in digital subtraction angiography or the postoperative pathological discovery of HCC tumor cells. A significant difference was observed between the active and inactive residual groups in \u2206 HU difference between CT values of arterial phase and non-contrast scans (AN, <jats:italic toggle=\"yes\">P<\/jats:italic> = .000), difference between CT values of venous phase and non-contrast scans (VN, <jats:italic toggle=\"yes\">P<\/jats:italic> = .000), difference between CT values of delay phase and non-contrast scans (DN, <jats:italic toggle=\"yes\">P<\/jats:italic> = .000), (difference between CT values of venous and arterial phase scans, <jats:italic toggle=\"yes\">P<\/jats:italic> = .001), and (difference between CT values of delay and arterial phase scans, <jats:italic toggle=\"yes\">P<\/jats:italic> = .005). No statistically significant difference was observed between the delayed and venous phases (difference between CT values of delay and venous phase scans, <jats:italic toggle=\"yes\">P<\/jats:italic> = .361). The area under the curve (AUC) of the ROC curve showed that the diagnostic efficacies in difference in CT value of AN (AUC = 0.976), VN (AUC = 0.927), and DN (AUC = 0.924) were higher, and their cutoff values were 4.86, 12.065, 20.19 HU with their sensitivities of 93.3%, 84.4%, 77.8% and specificities of 100%, 96.4%, and 100%, respectively. difference in CT value values of AN<jats:sub>,<\/jats:sub> VN, DN, difference between CT values of venous and arterial phase scans and difference between CT values of delay and arterial phase scans can sensitively detect residual tumor activity 20-40 days after DEB-TACE. Thus, more sensitive active residual foci were detected using all 3 enhanced phases rather than only the arterial phase. Quantitative analysis of multiphase CECT can detect residual tumor activity in an early and noninvasive manner, which can provide time for patients to receive early follow-up treatment.<\/jats:p>","DOI":"10.1097\/md.0000000000034054","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T18:04:46Z","timestamp":1686938686000},"page":"e34054","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Quantitative analysis with multiphase contrast-enhanced computed tomography to evaluate residual tumor activity of hepatocellular carcinoma after DEB-TACE"],"prefix":"10.1097","volume":"102","author":[{"given":"Wenchao","family":"Hu","sequence":"first","affiliation":[{"name":"Graduate School, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"},{"name":"Department of Radiology, Shulan Hangzhou Hospital, Affiliated to Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohong","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Radiology, Shulan Hangzhou Hospital, Affiliated to Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengli","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Radiology, Shulan Hangzhou Hospital, Affiliated to Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3407-4393","authenticated-orcid":false,"given":"Jianfeng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Shulan Hangzhou Hospital, Affiliated to Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiology, Shulan Hangzhou Hospital, Affiliated to Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9638-1703","authenticated-orcid":false,"given":"Guoliang","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Interventional Treatment, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/ijc.30211","article-title":"International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007.","volume":"139","author":"Petrick","year":"2016","journal-title":"Int J Cancer"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study.","volume":"5","author":"Fitzmaurice","year":"2019","journal-title":"JAMA Oncol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"635731","DOI":"10.3389\/fonc.2021.635731","article-title":"The progress in the treatment of hepatocellular carcinoma with portal vein tumor thrombus.","volume":"11","author":"Luo","year":"2021","journal-title":"Front Oncol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update.","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s12072-010-9165-7","article-title":"Asian Pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma.","volume":"4","author":"Omata","year":"2010","journal-title":"Hepatol Int"},{"issue":"Suppl 19","key":"R6-20250504","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00535-008-2244-z","article-title":"Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines.","volume":"44","author":"Kokudo","year":"2009","journal-title":"J Gastroenterol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma.","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases.","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1200\/JCO.2006.09.8657","article-title":"Transcatheter and ablative therapeutic approaches for solid malignancies.","volume":"25","author":"Liapi","year":"2007","journal-title":"J Clin Oncol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.3748\/wjg.v21.i12.3462","article-title":"Management of hepatocellular carcinoma with portal vein thrombosis.","volume":"21","author":"Quirk","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3350\/cmh.2015.21.4.344","article-title":"Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: now and future.","volume":"21","author":"Woo","year":"2015","journal-title":"Clin Mol Hepatol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.3748\/wjg.v25.i32.4614","article-title":"Locoregional treatments for hepatocellular carcinoma: current evidence and future directions.","volume":"25","author":"Inchingolo","year":"2019","journal-title":"World J Gastroenterol"},{"key":"R13-20250504","first-page":"597","article-title":"Resection of hepatocellular carcinoma following transcatheter hepatic artery embolization.","volume":"9","author":"Teng","year":"1994","journal-title":"Chin J Radiol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","article-title":"Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the study of the liver.","volume":"35","author":"Bruix","year":"2001","journal-title":"J Hepatol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2013.01.039","article-title":"Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.","volume":"58","author":"Jung","year":"2013","journal-title":"J Hepatol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1148\/radiol.11110282","article-title":"Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models.","volume":"262","author":"Shim","year":"2012","journal-title":"Radiology"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jhep.2011.03.007","article-title":"EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization.","volume":"55","author":"Gillmore","year":"2011","journal-title":"J Hepatol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3348\/kjr.2018.0088","article-title":"Update on transarterial chemoembolization with drug-eluting microspheres for hepatocellular carcinoma.","volume":"20","author":"Nouri","year":"2019","journal-title":"Korean J Radiol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol Int"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1148\/radiology.202.2.9015062","article-title":"Nodular hepatocellular carcinomas: detection with arterial-, portal-, and delayed-phase images at spiral CT.","volume":"202","author":"Hwang","year":"1997","journal-title":"Radiology"},{"key":"R22-20250504","first-page":"53","article-title":"Tomografia Computerizzata spirale multifasica del piccolo epatocarcinoma: ottimizzazione metodologica e interesse diagnostico [multiple-phase spiral computerized tomography of small hepatocellular carcinoma: technique optimization and diagnostic yield].","volume":"98","author":"Catalano","year":"1999","journal-title":"Radiol Med"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s003300000633","article-title":"Biphasic spiral CT of the liver: automatic bolus tracking or time delay?","volume":"11","author":"Mehnert","year":"2001","journal-title":"Eur Radiol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/0046-8177(92)90316-U","article-title":"Vascular supply in adenomatous hyperplasia of the liver and hepatocellular carcinoma: a morphometric study.","volume":"23","author":"Ueda","year":"1992","journal-title":"Hum Pathol"},{"key":"R25-20250504","first-page":"4","article-title":"The spiral CT manifestations of the blood supply of primary hepatocellular carcinoma: correlation with pathologic findings.","volume":"34","author":"Huang","year":"2000","journal-title":"Chin J Radiol"},{"key":"R26-20250504","first-page":"3383","article-title":"Blood supply characteristics of pedunculated hepatocellular carcinoma prior to and following transcatheter arterial chemoembolization treatment: an angiographic demonstration.","volume":"15","author":"Huang","year":"2018","journal-title":"Oncol Lett"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1038\/ctg.2017.28","article-title":"Targeting the vasculature in hepatocellular carcinoma treatment: starving versus normalizing blood supply.","volume":"8","author":"Liu","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1148\/radiol.2343031362","article-title":"Perfusion imaging of the liver: current challenges and future goals.","volume":"234","author":"Pandharipande","year":"2005","journal-title":"Radiology"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.3748\/wjg.v10.i19.2878","article-title":"Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level.","volume":"10","author":"Li","year":"2004","journal-title":"World J Gastroenterol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4997\/jrcpe.2017.306","article-title":"Is it safe to use gadolinium-based contrast agents in MRI?","volume":"47","author":"Pullicino","year":"2017","journal-title":"J R Coll Physicians Edinb"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/RLI.0000000000000417","article-title":"The effect of perinatal gadolinium-based contrast agents on adult mice behavior.","volume":"53","author":"Khairinisa","year":"2018","journal-title":"Invest Radiol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"e0230024","DOI":"10.1371\/journal.pone.0230024","article-title":"Respiratory motion artefacts in Gd-EOB-DTPA (Primovist\/Eovist) and Gd-DOTA (Dotarem)-enhanced dynamic phase liver MRI after intensified and standard pre-scan patient preparation: a bi-institutional analysis.","volume":"15","author":"Wybranski","year":"2020","journal-title":"PLoS One"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17090","article-title":"Contrast-enhanced ultrasound using SonoVue (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis.","volume":"17","author":"Westwood","year":"2013","journal-title":"Health Technol Assess"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:09:58Z","timestamp":1746320998000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":33,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000034054","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,16]]}}}